The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

The trial results are critical, as it brings Eli Lilly's pill one step closer to becoming a new, needle-free alternative for ...

The WHO plans to reduce its workforce and budget by over 20% due to reduced U.S. funding, according to an internal memo. Meanwhile, an Eli Lilly trial showed their experimental drug lepodisiran cut a ...

Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...

Eli Lilly's experimental drug, lepodisiran, showcased remarkable efficacy in reducing lipoprotein(a) levels, a heart disease risk factor, by up to 95% in a midstage trial. The innovative treatment ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could ...

Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly (NYSE:LLY) announced an expansion of its LillyDirect digital healthcare platform to facilitate contact with ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...